Vanda Pharmaceuticals Inc
VNDA7.570USD
+0.340+4.70%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
447.35MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vanda Pharmaceuticals Inc Unternehmen
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Vanda Pharmaceuticals Inc Informationen
BörsenkürzelVNDA
Name des UnternehmensVanda Pharmaceuticals Inc
IPO-datumApr 12, 2006
CEOPolymeropoulos (Mihael Hristos)
Anzahl der mitarbeiter368
WertpapierartOrdinary Share
GeschäftsjahresendeApr 12
AddresseSuite 300E
StadtWASHINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20037
Telefon12027343400
Websitehttps://www.vandapharma.com/
BörsenkürzelVNDA
IPO-datumApr 12, 2006
CEOPolymeropoulos (Mihael Hristos)
Führungskräfte von Vanda Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+10000.00%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+174050.00%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+178386.00%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+59225.00%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+59225.00%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+59225.00%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
97.08K
+52225.00%
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+10000.00%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+174050.00%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+178386.00%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+59225.00%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+59225.00%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+59225.00%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Fanapt
31.25M
55.54%
Hetlioz
17.98M
31.96%
PONVORY
7.04M
12.50%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Fanapt
31.25M
55.54%
Hetlioz
17.98M
31.96%
PONVORY
7.04M
12.50%
Aktionärsstatistik
Aktualisiert: Wed, Feb 4
Aktualisiert: Wed, Feb 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
9.77%
The Vanguard Group, Inc.
6.26%
Renaissance Technologies LLC
5.88%
Dimensional Fund Advisors, L.P.
4.34%
Tang Capital Management, LLC
3.98%
Andere
69.76%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
9.77%
The Vanguard Group, Inc.
6.26%
Renaissance Technologies LLC
5.88%
Dimensional Fund Advisors, L.P.
4.34%
Tang Capital Management, LLC
3.98%
Andere
69.76%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
28.50%
Investment Advisor/Hedge Fund
26.31%
Hedge Fund
17.28%
Individual Investor
7.19%
Private Equity
2.47%
Research Firm
1.71%
Pension Fund
0.27%
Bank and Trust
0.20%
Sovereign Wealth Fund
0.19%
Andere
15.86%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
345
45.94M
77.74%
-10.37M
2025Q3
373
46.45M
78.60%
-9.99M
2025Q2
417
50.75M
85.90%
-11.31M
2025Q1
426
48.51M
82.37%
-12.27M
2024Q4
444
46.48M
79.71%
-15.23M
2024Q3
446
47.42M
81.36%
-14.93M
2024Q2
445
46.99M
80.73%
-18.42M
2024Q1
434
53.50M
92.97%
-11.41M
2023Q4
445
55.38M
96.27%
-9.21M
2023Q3
446
56.79M
98.75%
-12.15M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
5.77M
9.77%
-211.76K
-3.54%
Sep 30, 2025
The Vanguard Group, Inc.
3.56M
6.02%
+14.34K
+0.40%
Sep 30, 2025
Renaissance Technologies LLC
3.48M
5.88%
+29.46K
+0.85%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
2.56M
4.34%
-21.79K
-0.84%
Sep 30, 2025
Tang Capital Management, LLC
2.35M
3.98%
--
--
Sep 30, 2025
Polymeropoulos (Mihael Hristos)
2.34M
3.95%
+10.00K
+0.43%
Aug 07, 2025
BlackRock Financial Management, Inc.
2.25M
3.8%
-186.40K
-7.66%
Sep 30, 2025
Acadian Asset Management LLC
2.23M
3.77%
+496.85K
+28.69%
Sep 30, 2025
Millennium Management LLC
3.25M
5.5%
+130.50K
+4.18%
Sep 30, 2025
Two Sigma Investments, LP
1.57M
2.66%
+235.54K
+17.63%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Neuroscience and Healthcare ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.49%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
ALPS Medical Breakthroughs ETF
0.1%
Federated Hermes MDT Small Cap Core ETF
0.09%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Franklin US Small Cap Multifactor Index ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.03%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil0.49%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.49%
SPDR SSGA US Small Cap Low Volatility Index ETF
Anteil0.12%
ALPS Medical Breakthroughs ETF
Anteil0.1%
Federated Hermes MDT Small Cap Core ETF
Anteil0.09%
iShares Micro-Cap ETF
Anteil0.05%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Franklin US Small Cap Multifactor Index ETF
Anteil0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.04%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Anteil0.03%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
